J. Goldman & Co’s DexCom DXCM Stock Holding History

J. Goldman & Co’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-22,500	Closed	-$2.79M	–	436
2023 Q4	$2.79M	Buy	+22,500	New	+$2.3M	0.11%	166

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

J. Goldman & Co's DXCM Position: Q1 2019 in Review

J. Goldman & Co sold out of DexCom (DXCM) in Q1 2019, closing a stake of 170,652 shares — an estimated $5.11M sold.

J. Goldman & Co first reported a position in DXCM in Q4 2018 and held it in 1 quarter. The position peaked at $5.11M in Q4 2018. 457 funds tracked by Wall St. Rank hold DXCM as of Q1 2019.

J. Goldman & Co reported no remaining DexCom position as of Q1 2019 after selling out during the quarter.
J. Goldman & Co sold 170,652 DexCom shares in Q1 2019, an estimated $5.11M.
J. Goldman & Co first reported a position in DexCom in Q4 2018 and held it in 1 quarter.
J. Goldman & Co's DexCom position peaked at $5.11M in Q4 2018.
457 funds tracked by Wall St. Rank held DexCom as of Q1 2019.

Based on J. Goldman & Co's 13F filing for Q1 2019, filed 14 May 2019.